Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

37.16+0.19 (+0.51%)

At close: 4:02PM EDT

37.18 +0.01 (0.03%)
Pre-Market: 8:23AM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	36.97
Open	37.41
Bid	37.18 x 4000
Ask	37.19 x 1300
Day's Range	36.89 - 37.65
52 Week Range	29.99 - 43.08
Volume	33,066,084
Avg. Volume	31,839,998

Market Cap	207.284B
Beta (5Y Monthly)	0.65
PE Ratio (TTM)	21.77
EPS (TTM)	1.71
Earnings Date	May 04, 2021
Forward Dividend & Yield	1.56 (4.20%)
Ex-Dividend Date	Jan 28, 2021
1y Target Est	40.54

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-22% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Editor's Pick
Yahoo Finance
Johnson & Johnson vaccine setback sends shares of stay-at-home stocks like Zoom higher
The stay-at-home stocks quickly came back into favor on news of a setback with Johnson & Johnson's single-dose COVID-19 vaccine.
- Doctor on J&J vaccine: 'We’re talking about one in a million for these clots'
  Yahoo Finance Video
- How COVID-19 transformed the biotech industry
  Yahoo Finance Video
Editor's Pick
Yahoo Finance Video
Stock market reaction to J&J vaccine pause is ‘pretty modest’: economist
Michael Darda, Chief Economist & Macro Strategist at MKM Partners joins Yahoo Finance Live to discuss the outlook for economic recovery after U.S. regulators called for a pause in the use of Johnson & Johnson’s COVID-19 vaccine.
- Canada talking to J&J about vaccine setback as PM frets over virus variants
  Reuters
- J&J Announcement Impacts Vaccination Sites Across South Florida
  CBS Miami - WFOR
Reuters
UPDATE 1-EU to raise COVID vaccine supplies from Pfizer in Q2 to 250 mln doses
European Union countries will receive 50 million more coronavirus vaccines produced by Pfizer and BioNTech in the second quarter, the head of the EU Commission said on Wednesday, as deliveries expected at the end of the year will be brought forward. European Commission President Ursula von der Leyen said the earlier deliveries, which will start this month instead of in October, will take total supplies to the EU from Pfizer to 250 million doses in the second quarter in a move meant to compensate for lower supplies from AstraZeneca and possible problems with Johnson & Johnson. Von der Leyen confirmed the Commission was in talks with Pfizer and BioNTech for a new contract for 1.8 billion doses to be delivered in 2022 and 2023, confirming a Reuters report last week.